

# Charles E Inturrisi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2821377/publications.pdf>

Version: 2024-02-01

44  
papers

3,125  
citations

279798

23  
h-index

276875

41  
g-index

44  
all docs

44  
docs citations

44  
times ranked

2072  
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding Opioid Actions, Pain and Analgesia: A Tribute to Dr. Gavril Pasternak. Cellular and Molecular Neurobiology, 2021, 41, 827-834.	3.3	0
2	The effect of obesity on pain severity and pain interference. Pain Management, 2021, 11, 571-581.	1.5	7
3	The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats.. Experimental and Clinical Psychopharmacology, 2020, 28, 196-201.	1.8	18
4	Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy. Journal of Opioid Management, 2020, 16, 111-118.	0.5	5
5	Does transdermal fentanyl work in patients with low BMI? Patient-reported outcomes of pain and percent pain relief in cancer patients on transdermal fentanyl. Cancer Medicine, 2019, 8, 7516-7522.	2.8	4
6	Characterization of the Safety and Pharmacokinetic Profile of d-Methadone, a Novel N-Methyl-d-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects. Journal of Clinical Psychopharmacology, 2019, 39, 226-237.	1.4	24
7	Patient-Reported Outcomes and Opioid Use by Outpatient Cancer Patients. Journal of Pain, 2018, 19, 278-290.	1.4	18
8	Patient-Reported Outcomes and Opioid Use in Outpatients With Chronic Pain. Journal of Pain, 2017, 18, 583-596.	1.4	7
9	The Tri-Institutional Pain Registry Analysis of Outpatient Pain Management at a Specialized Cancer Center. Pain Medicine, 2017, 18, 2474-2484.	1.9	6
10	Using Chronic Pain Outcomes Data to Improve Outcomes. Anesthesiology Clinics, 2016, 34, 395-408.	1.4	6
11	Pain Assessment, Management, and Control Among Patients 65 Years or Older Receiving Hospice Care in the U.S.. Journal of Pain and Symptom Management, 2016, 52, 663-672.	1.2	20
12	Methadone Safety: A Clinical Practice Guideline From the American Pain Society and College on Problems of Drug Dependence, in Collaboration With the Heart Rhythm Society. Journal of Pain, 2014, 15, 321-337.	1.4	203
13	Stabilization of the $\mu$ -Opioid Receptor by Truncated Single Transmembrane Splice Variants through a Chaperone-like Action. Journal of Biological Chemistry, 2013, 288, 21211-21227.	3.4	51
14	Personalized Medicine and Opioid Analgesic Prescribing for Chronic Pain: Opportunities and Challenges. Journal of Pain, 2013, 14, 103-113.	1.4	98
15	Improving the Pharmacologic Management of Pain in Older Adults: Identifying the Research Gaps and Methods to Address Them. Pain Medicine, 2011, 12, 1336-1357.	1.9	93
16	Consensus guideline on parental methadone use in pain and palliative care. Palliative and Supportive Care, 2008, 6, 321-321.	1.0	0
17	Estradiol and progesterone differentially regulate formalin-induced nociception in ovariectomized female rats. Hormones and Behavior, 2006, 49, 441-449.	2.1	79
18	Pharmacology of analgesia: basic principles. , 2003, , 111-123.		1

#	ARTICLE	IF	CITATIONS
19	Clinical Pharmacology of Opioids for Pain. <i>Clinical Journal of Pain</i> , 2002, 18, S3-S13.	1.9	498
20	Retinoic acid regulation of mu opioid receptor and c-fos mRNAs and AP-1 DNA binding in SH-SY5Y neuroblastoma cells. <i>Molecular Brain Research</i> , 2002, 99, 34-39.	2.3	21
21	Dynorphin A(1-13) Analgesia in Opioid-Treated Patients with Chronic Pain. <i>Clinical Drug Investigation</i> , 1999, 17, 33-42.	2.2	10
22	Retinoic acid-induced increase in delta-opioid receptor and N-Methyl-d-Aspartate receptor mRNA levels in neuroblastoma and glioma (NG108-15) cells. <i>Brain Research Bulletin</i> , 1996, 39, 193-199.	3.0	22
23	NMDA antagonists and clonidine block c-fos expression during morphine withdrawal. <i>Synapse</i> , 1995, 20, 68-74.	1.2	43
24	N-Methyl-D-Aspartate (NMDA) Receptors, Mu and Kappa Opioid Tolerance, and Perspectives on New Analgesic Drug Development. <i>Neuropsychopharmacology</i> , 1995, 13, 347-356.	5.4	109
25	Antisense Oligodeoxynucleotides to the Cloned $\delta$ Receptor DOR $\alpha$ 1: Uptake, Stability, and Regulation of Gene Expression. <i>Journal of Neurochemistry</i> , 1995, 65, 1981-1987.	3.9	37
26	Section Review Central & Peripheral Nervous Systems: Pharmacological Modulation of Opioid Tolerance. <i>Expert Opinion on Investigational Drugs</i> , 1995, 4, 271-281.	4.1	8
27	Acute and Persistent Suppression of Preproenkephalin mRNA Expression in the Striatum Following Developmental Hypoxic-Ischemic Injury. <i>Journal of Neurochemistry</i> , 1994, 62, 1878-1886.	3.9	25
28	Metrazole induction of c-fos and proenkephalin gene expression in the rat adrenal and hippocampus: pharmacological characterization. <i>Molecular Brain Research</i> , 1993, 20, 118-124.	2.3	15
29	Naltrexone Maintenance. <i>American Journal on Addictions</i> , 1993, 2, 34-38.	1.4	1
30	Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers. <i>American Journal on Addictions</i> , 1993, 2, 34-38.	1.4	4
31	The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 422-431.	4.7	126
32	Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 565-577.	4.7	104
33	Sublingual absorption of selected opioid analgesics. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 335-342.	4.7	245
34	Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 392-401.	4.7	233
35	Cerebrospinal fluid pharmacokinetics of intrathecal morphine sulfate and D-Ala <sup>2</sup> -D-Leu <sup>5</sup> -enkephalin. <i>Annals of Neurology</i> , 1986, 20, 218-222.	5.3	25
36	Epidural and intrathecal opiates: Cerebrospinal fluid and plasma profiles in patients with chronic cancer pain. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 631-641.	4.7	90

#	ARTICLE	IF	CITATIONS
37	Central nervous system excitatory effects of meperidine in cancer patients. <i>Annals of Neurology</i> , 1983, 13, 180-185.	5.3	416
38	?-ENDORPHIN IMMUNOREACTIVITY IN THE PLASMA OF PSYCHIATRIC PATIENTS RECEIVING ELECTROCONVULSIVE TREATMENT. <i>Annals of the New York Academy of Sciences</i> , 1982, 398, 413-423.	3.8	32
39	Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 157-167.	4.7	61
40	Effects of acetylmethadol on plasma testosterone. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 19, 371-374.	4.7	24
41	DISPOSITION OF NARCOTICS AND NARCOTIC ANTAGONISTS. <i>Annals of the New York Academy of Sciences</i> , 1976, 281, 273-287.	3.8	33
42	Disposition of propoxyphene and norpropoxyphene in man after a single oral dose. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 15, 302-309.	4.7	45
43	The levels of methadone in the plasma in methadone maintenance. <i>Clinical Pharmacology and Therapeutics</i> , 1972, 13, 633-637.	4.7	133
44	Disposition of methadone in man after a single oral dose. <i>Clinical Pharmacology and Therapeutics</i> , 1972, 13, 923-930.	4.7	125